Article | December 15, 2020

Top 3 Do's And Don'ts To Boost Diversity In Clinical Trials

Source: Citeline

By Darcy Grabenstein, Senior Manager of Content Marketing Strategy, Citeline

Patient Diversity (002)

As the race for a coronavirus vaccine has painfully brought to light, minority groups remain grossly underrepresented in clinical trials. A recent study of all published COVID-19 treatment-related clinical research studies with participants in the United States revealed that one-third of the studies did not report race or ethnicity data. One study did not even collect race data among participants. The study revealed that Black patients were underrepresented in all studies relative to the burden of disease among the Black communities in which these studies took place.

Lack of diversity spans all disease states and demographics. Why is it important that these groups be represented in clinical trials? As we’ve seen with COVID-19, individuals from minority groups often have higher incidences of certain diseases. Plus, patients can respond differently to medical treatments, oftentimes with adverse or fatal reactions, due their ethnicity.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader